Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Early diagnosis and adequate staging are crucial for the choice of adequate treatment in prostate cancer (PC). Morphologic and functional imaging modalities, such as CT and MRI, have had limited accuracy in the diagnosis and nodal staging of PC. Molecular PET/CT imaging with C- or F-choline-labeled derivatives is increasingly being used, but its role in the diagnosis and initial staging of PC is controversial because of limitations in sensitivity and specificity for the detection of primary PC. For T staging, functional MRI is superior to C- or F-choline PET/CT. For N staging, C- or F-choline PET/CT can provide potentially useful information that may influence treatment planning. For the detection of bone metastases, C- or F-choline PET/CT has had promising results; however, in terms of cost-effectiveness, the routine use of C- or F-choline PET/CT is still debatable. C- or F-choline PET/CT might be used in high-risk PC before radiation treatment planning, potentially affecting this planning (e.g., regarding dose escalation). This review provides an overview of the diagnostic accuracy and limitations of C- or F-choline PET/CT in the diagnosis and staging of PC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.115.169748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is the F-choline PET-CT more cost-effective than standard protocol for locating a parathyroid adenoma?
Langenbecks Arch Surg
July 2025
Department of Surgery, University of Valencia, Valencia, Spain.
Purpose: The most common cause (> 80% of cases) of primary hyperparathyroidism (PHPT) is parathyroid adenoma. Its diagnosis is conventionally made by cervical ultrasound and Tc-MIBI scintigraphy. However [F-Choline PET-CT ( [F-FCh PET-CT) offers greater sensitivity and specificity, although at a high cost, which prevents it from being a first-line diagnostic method.
View Article and Find Full Text PDFIntroduction: As PET/CT's role in oncology expands, with increasing demands for staging, restaging, and therapy monitoring across a range of malignancies, and with the rise of theranostics, PET facilities are experiencing higher workloads, raising concerns about the accuracy of reports. This prospective study evaluates the frequency and nature of errors identified through a double-reading protocol.
Materials And Methods: Patients scheduled for baseline or follow-up PET/CT scans were prospectively included in the study between May and June 2024.
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes.
Onco Targets Ther
May 2025
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Purpose: There is an urgent need of biomarkers to personalize metastatic castration-resistant prostate cancer (mCRPC) treatment. A new prognostic model described by our group combines molecular characteristics (ptDNA levels), metabolic features from PET-scans (metabolic tumor volume), clinical parameters (visceral metastases), and lab tests (lactate-dehydrogenase levels) in abiraterone or enzalutamide-treated patients. This study aims to validate the score on mCRPC patients undergoing taxane treatment.
View Article and Find Full Text PDF[Patients with pHPT and negative standard imaging or with recurrent disease benefit from preoperative F-choline PET/CT].
Chirurgie (Heidelb)
July 2025
Klinik für Visceral‑, Thorax- und Gefäßchirurgie, Philipps-Universität Marburg, Baldingerstraße, 35043, Marburg, Deutschland.
F-choline PET/CT in the study of primary hyperparathyroidism: Evaluation of the technique, visual and semi-quantitative analysis and correlation with other imaging techniques.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
August 2025
Nuclear Medicine Department, University Hospital of Salamanca, Area of Radiology and Physical Medicine, University of Salamanca, Salamanca, Spain. Electronic address:
Objective: To assess the usefulness of performing a dual-time-point protocol in the acquisition of F-choline (F-FCH) PET/CT in the pre-surgical localization of PHPT, and to demonstrate the impact of this imaging technique on the management and outcome-based surgical decision making, compared to other imaging techniques. To evaluate the diagnostic performance of the test to discriminate between pathological parathyroid gland and cervical lymph node, as well as to establish its correlation with other imaging techniques (scintigraphy, ultrasound, CT and MRI).
Patients And Methods: We included 39 patients who underwent surgery for PHPT, in whom dual-time-point F-FCH PET/CT was performed.